Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer
March 04, 2021 09:00 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2...
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
February 23, 2021 08:00 ET
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
Celsion Corporation Announces Formation of Vaccine Advisory Board
February 12, 2021 08:30 ET
|
Celsion CORP
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) --...
Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years
January 27, 2021 20:30 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
January 22, 2021 08:40 ET
|
Celsion CORP
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
Allarity Therapeutics Provides Update on Dovitinib Program
October 23, 2020 02:35 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (23 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced several updates related to its planned filing of a new drug...
Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 08:00 ET
|
Celsion CORP
Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival;Data Maturity at Issue Conference Call...
Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival
August 04, 2020 08:30 ET
|
Celsion CORP
Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the...
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
July 27, 2020 08:30 ET
|
Celsion CORP
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for...
Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
June 25, 2020 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J, June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC)...